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ABSTRACT 
Kidney transplantation has become more resource intensive as recipient complexity has increased and 
average donor quality has diminished over time.  A national retrospective cohort study was performed 
to assess the impact of kidney donor and recipient characteristics on transplant center cost (exclusive of 
organ acquisition) and Medicare reimbursement.  Data from the national transplant registry, University 
HealthSystem Consortium hospital costs, and Medicare payments for deceased donor (N=53,862) and 
living donor (N=36,715) transplants from 2002-2013 were linked and analyzed using multivariate linear 
regression modeling. Deceased donor kidney transplant costs were correlated with recipient (Expected 
Post Transplant Survival Score, degree of allosensitization, obesity, cause of renal failure) donor (age, 
cause of death, donation after cardiac death, terminal creatinine), and transplant (histocompatibility 
matching) characteristics.  Living donor costs rose sharply with higher degrees of allosensitization, and 
were also associated with obesity, cause of renal failure, recipient work ability, and 0-ABDR 
mismatching. Analysis of Medicare payments for a subsample of 24,809 transplants demonstrated 
minimal correlation with patient and donor characteristics.  In conclusion, the complexity in the 
landscape of kidney transplantation increases center costs, posing financial disincentives that may 
reduce organ utilization and limit access for higher risk populations.  
INTRODUCTION 
The practice of kidney transplantation has become more complex as a result of changing 
recipient demographics, declining organ quality, and broader application of treatments to address 
allosensitization.  In the US, there has been a 250% increase in the proportion of patients older than 
age 65 years old at the time of transplantation.(1) In the US, elderly patients (>65) now represent 
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over a quarter of all transplant recipients.(2)  While clinically successful, kidney transplant in the 
elderly is associated with a marked increase in the incidence of perioperative complications and 
extended length of stay.(3, 4)    Similarly, the prevalence of obesity, diabetes, coronary artery disease, 
and peripheral vascular disease have increased as transplant eligibility criteria evolve to reflect the 
changing nature of the end stage renal disease (ESRD) population. Equally challenging is the 
increasing prevalence of transplant recipients with high levels of allosensitization.  Renal transplant in 
patients with panel reactive antibody (PRA) or calculated PRA (cPRA) levels greater than 80 than have 
increased by over 300% from 2000 to 2013, a trend that has accelerated with the new US allocation 
system.(5) These highly sensitized patients require an increased intensity of peri-operative treatment 
including the need for plasmapheresis, intravenous immunoglobulin, and high cost induction 
therapy.(6)  Despite a higher incidence of peri-operative complications, post-transplant survival in the 
highly sensitized patient is excellent and markedly improved compared to patients on dialysis. (6, 7)   
Increased resource utilization has also been driven by the ongoing shortage of high quality 
donor organs. Nationally, the kidney transplant waiting list has expanded to over 100,000 patients, 
while deceased donor availability has only marginally increased and living donor transplants are 
diminishing.(1)  To meet this demand, transplant programs now use donor kidneys with high terminal 
creatinine, organs from older donors, and organs donated after cardiac death (DCD).(8, 9) These 
kidneys are life-saving when used in the appropriate patient population, yet each has been 
associated with higher rates of delayed graft function, rehospitalization, need for pulsatile perfusion, 
and use of cell depleting antibody therapy , all of which may add cost to the transplant episode.(10, 
11)  
Prior economic analyses of kidney transplantation have focused on the global cost 
effectiveness of renal care.  When compared with dialysis, renal transplant has been shown to 
improve outcomes and reduce long term medical expenditures even for high risk patients.(12-14)  
These savings, unfortunately, accrue over time and the cost of the initial transplant procedure is 
borne by the transplant center which does not benefit from long term cost savings.  Current 
reimbursement for kidney transplant under the Medicare program in the United States, which is the 
largest payer for transplant services in the world, has been generally static over the past ten years. 
Kidney transplant centers are paid based on a single diagnosis related group (DRG) which, unlike 
heart or liver transplant, is not adjusted for recipient complexity or donor factors.  Consequently, 
increase in the direct cost of transplant care for higher risk patients unaccompanied by increased 
payment may threaten the economic viability of many transplant programs.(15, 16)  
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 The purpose of this investigation was to examine the impact of the changing donor and 
recipient characteristics on cost and payments in a national sample of US kidney transplant programs. 
Using a novel database incorporating linked cost accounting data, transplant registry data, and third 
party payer data, we performed the first national analysis of the financial implications of the 
increasing complexity of kidney transplant care in the modern era.   
 
 
 
METHODS 
Data Sources 
A nationally representative database was created by linking clinical and demographic 
information from the national transplant registry with financial data provided by the University 
HealthSystem Consortium (UHC) for renal transplants (N=90,577) performed between 2002-2013.  
This study used data from the Organ Procurement and Transplantation Network (OPTN). The OPTN 
data system includes data on all donor, wait-listed candidates, and transplant recipients in the U.S., 
submitted by the members of the OPTN, and has been described elsewhere (17). The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human Services 
provides oversight to the activities of the OPTN contractor. The UHC data is drawn from 105 academic 
transplant centers within the United States. UHC data includes patient level claims data from 
administrative billing claims submissions, adjusted to costs using the transplant hospital’s Medicare 
cost to charge ratio and adjusted for geographic differential in wages.  Transplant records were linked 
using date of transplant, age, and gender, as previously describe. The UHC population is similar to the 
overall US kidney renal transplant population (Supplemental Table 1). To eliminate misclassified cases 
and clinical outliers, we restricted the analysis to patients with a minimal cost of $30,000 including 
organ acquisition to eliminate non-transplant admissions, and a maximum cost of $200,000 which 
represented the 98th
Medicare payments were then obtained for patients with Medicare fee for service insurance 
who underwent kidney transplant between 2002-2013 at a UHC center. To merge OPTN and Medicare 
data, beneficiary identifiers from Medicare files were linked to OPTN records using Social Security 
number, gender, and date of birth.  The merge and data cohort generation transplant analysis was 
described in previous publications.(18)  For this cohort, we required a minimum payment of $10,000 
 percentile for costs. Cost was adjusted to 2013 dollars using the healthcare 
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(excluding organ acquisition cost center [OAC]) to eliminate non-transplant admissions. Because 
Medicare claims do not include OAC payment (which is paid via the institutional cost report), 
Medicare payments reflect only the reimbursement obtained through the transplant DRG and any 
outlier payments. Consequently, direct calculation of hospital margin is not possible using these data 
as cost accounting systems and allocation of costs to the OAC may vary over time and between 
institutions. Medicare payment estimates were also adjusted to account for differential payments by 
Medicare to transplant programs in Maryland due to that state’s Medicare payment waiver by 
removing costs recorded as related to OAC for these centers. 
 
Variable Definitions 
We calculated the Expected-Post Transplant Survival (EPTS) and Kidney Donor Profile Index 
(KPDI) score as described by the SRTR.(19)  Patients were classified on the basis of body mass index 
(BMI, kg/m2
   
) as underweight (BMI <18.5, normal(18.5 to < 25), overweight (25 to <30), obese (30 to 
<35), and morbidly obese (> 35).  To adjust for the degree of allosensitization over the duration of the 
study, we incorporated several different measures into the “PRA” variable.  When available, we used 
the calculated panel reactive antibody (cPRA) recorded at the time of transplant. For patients 
transplanted prior to routine use of cPRA, we incorporated the PRA at the time of transplant when 
available or the peak PRA if no PRA at transplant was recorded.(20) Other variables including cause of 
ESRD, cause of donor death, and payer definitions were based on OPTN records.  
Cost model regression analysis 
Multivariable linear regression was used to estimate the impact of donor and recipient 
characteristics on center costs and Medicare payment.  Total transplant cost inclusive of OAC was 
examined as this represents the total cost of transplant care delivered at the center.  This cost is 
relevant for centers receiving private insurance reimbursement as reimbursement for OAC is 
frequently included in the global reimbursement.  
Initial cost modeling was performed using EPTS and KPDI index values. While EPTS was found 
to correlate with overall cost, the KDPI in aggregate did not (p>.010).  However, component variables 
within KPDI were significant in the multivariate analysis, and were retained in the analysis. Variables 
were retained in the model if the p value for its association, or for a level of a categorical factor, was 
less than 0.10 or the variable was part of a set of mutually exclusive options (e.g. diagnosis).  Using the 
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cost models to adjust for donor and recipient characteristics, we then estimated the variation in the 
ratios of observed to expected in cost and profitability for transplant centers nationally.   
Data management and analysis was performed using SAS 9.4 software (SAS Institute, Cart, NC) 
and R 3.0 (R Foundation for Statistical Computing, Vienna, Austria).  
 
Approvals 
This study was approved by the Institutional Review Board at Saint Louis University School of 
Medicine.  The project was also reviewed and approved by the Centers for Medicare and Medicaid 
Services, HRSA, and UHC.  
 
 
RESULTS 
 The risk profile of kidney transplant recipients cared for in UHC member hospitals has changed 
dramatically between 2002-2003 and 2012-2013 (Table 1).  Among deceased donor recipients 
(N=53,862), the median age at transplant has increased from 51 to 55 years, while the percent of 
patients over than 60 years has increased by 30%.  In the more recent era, there are more patients 
transplanted with diabetes (25.5% vs. 23.0%), and the proportion of patients with more than 5 years 
of dialysis time has risen (29.0% vs. 22.5%). Consequently, the prevalence of patients with an EPTS 
score > 85 has increased (26.9% vs. 20.3%). UHC facilities are also transplanting substantially more 
patients with high levels of allosensitization defined as PRA > 80% (9.2% vs. 5.0%) and > 97% (1.8% vs. 
0.9%). Similar changes are evident in the recipients of living donor transplants (N=36,715) who are 
older (median age 49 vs. 46) and have greater degrees of allosensitization (PRA > 80: 2.5% vs. 1.1%).  
During the study period, the characteristics of the donor population and management of 
immunosuppression also changed, including increased utilization of deceased donor organs with 
higher risk characteristics including older age, higher creatinine, and a greater proportion of DCDs 
(P<0.0001).  There has also been a dramatic increase in the portion of kidney transplants which were 
placed on pulsatile perfusion, received cell depleting antibodies for induction, and had a history of 
diabetes.   
 Despite the increasing complexity of this population, transplant was highly successful.  
Unadjusted one-year graft survival increase from 89.7% in 2002-03 to 91.5% in 2012-13 for deceased 
donor transplant, and from 95.2% to 96.4% for living donor transplants.  There was, however, a higher 
incidence of delayed graft function (DGF) in deceased donor transplants (25.1% vs 22.9%). 
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Cost Analysis 
 During the study period, the median total reported cost per deceased donor transplant (N= 
53,862) performed at a UHC center increased from $97,892 in 2002-2003 to $106,675 in 2012-2013, 
after adjustment to 2013 dollars. This estimate includes OAC and perioperative care for the initial 
hospitalization. Univariate analysis revealed a strong association between recipient EPTS and the cost 
of the transplant procedure (p<0.0001) (Figure 1).  
 Multivariate modeling confirmed a strong association between recipient characteristics and 
cost of deceased donor transplant exclusive of organ acquisition cost (Table 2). Recipient EPTS was 
strongly associated with cost in the multivariate model.  Compared to patients with EPTS < 20, EPTS 
resulted in significant, graded increased in incremental costs (20-50: $1,095; 50-85 $2,292; >85: 
$5,257; p<0.005 for all).  Higher cPRA levels had strong, graded associations with higher transplant 
costs such that a cPRA 98-100 was associated with $9,097 of incremental expenditure (P<0.0001). 
Recipient characteristics associated with lower per transplant costs include polycystic kidney disease, 
female gender, and working at the time of transplant.  
 Donor quality also had a significant impact on the expected cost of care.  Among deceased 
donor transplants, older age ($62 per year, p<0.0001), death due to anoxic injury, elevated terminal 
creatinine ($956 per mg/dl increase, p<0.0001), and DCD donation ($6182 p<0.0001) were 
independently associated with higher costs.  Costs were lower with 0-DR (-$2,968, p<0.0001) and 0-
ABDR mismatch total (-$4,332, p<0.0001) HLA antigen mismatches.   Finally, transplants using kidneys 
placed on a pulsatile perfusion pump were $2,039 less expensive (p<0.0001).   
 Among UHC centers, the unadjusted total cost per case (median $89,208, 25-75% percentiles: 
$74,361-$99,746) varied extensively.  After adjustment for donor and recipient factors, center level 
variation persisted with an observed-to-expected cost ratio varied from 0.50 to 1.51 for deceased 
donors. The ratio of observed-to-expected costs appears to be minimally associated with center 
volume (P<0.02) (Figure 2A).  Analysis at a regional level demonstrated higher than expected costs for 
deceased donor transplant performed in region 5, 7, and 10. Cost was lower in regions 1, 3, and 11. 
(Table 3).  
 Nationally, 36,715 living donor transplants were performed in UHC centers between 2002-
2013. The average cost increased over the period from $86,914 in 2002-2003 to $95,463 in 2012-
2013. Higher EPTS was associated with a non-statistically significant increase in costs. Recipient factors 
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associated with higher cost included live donor transplantation included African American race, higher 
BMI and increased cPRA. (Table 2b).  Increasing allosensitization dramatically increases costs, such 
that a cPRA of 98-100 was associated with $17,784 in additional cost compared with transplant in 
patients with a PRA of 0-20 (p<0.0001). Polycystic kidney disease and glomerular disease (compared 
with diabetes), working at the time of transplant, and 0-ABDR mismatch were all associated with 
lower costs. Female living donors were associated with modest decreases in costs.  Substantial 
variation in average risk-adjusted cost was also noted among living donor transplant (Figure 2B).  
Regionally, the ratio of observed to expected living donor transplant cost was highest in region 2 
(Michigan, Ohio, Indiana) and lowest in region 11 (Southeast US) (Table 3). 
` 
Payment 
 Medicare payment data were available for 24,765 deceased donor kidney recipients, 
representing 45.9% of the transplants performed at a UHC hospital.  Median CPI adjusted payment for 
renal transplant, not including organ acquisition payment, decreased from 2002-2003 ($40,222) to 
2012-2013 ($34,227).  Multivariate modeling demonstrated some association in Medicare payments 
and recipient characteristics. (Table 4A) Risk adjusted payment was $1,626 higher for patients with 
EPTS 51-85, and $2,475 dollars greater for EPTS greater than 85.  Payments were increased for African 
Americans and those of other race/ethnicities.  There was no association between transplant 
payments and cPRA.  Medicare payments were higher for recipients with donors who were older or 
had elevated terminal creatinine ($279 per mg/dl, P=0.01), but not significantly different for recipients 
of DCD organs (p=0.34).  They were lower for recipients of kidneys from pumped organs (-1,768, 
P<0.0001) and diabetic donors (-$1046, P<0.0001).   
 Medicare claims were reviewed for 8,165 living donor recipients, representing 22.2% of all 
living donor transplants performed at UHC centers.  Medicare payments were uncorrelated with 
recipient EPTS score (Table 3B). Characteristics associated with higher payments included female 
gender and working at transplant. Medicare payments did increase with PRA, such that the highest 
PRA (98-100) was associated with an incremental payment of $4,709.  Donor factors associated with 
higher payments included age of the donor, donors of “other race”, and participation in paired donor 
exchange ($5,956, P<0.0001).   
 Analysis of regional variation in Medicare payments demonstrated higher than expected 
payments in three UNOS regions ( 5, 7, and 10) and lower than expected payments in  two regions (1 
and  11).   Average payment for a deceased donor transplant varied by 18.9% ($37,019 to $45,570) 
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across centers.  Living donor transplant payment varied by 13.7% nationally $38,700-$44,868).  Average 
payment and total cost of transplant were not correlated for either deceased or living donor transplant 
(Figure 3).  
Discussion 
This national cohort analysis of the changing financial aspects of kidney transplant demonstrates 
the tremendous financial challenge facing US transplant programs as a result of the changing 
composition of the renal transplant population. Patients are older, have a greater burden of comorbid 
conditions, present with more dialysis time, and have higher levels of allosensitization. As a result, the 
prevalence of patients with elevated EPTS scores has increased dramatically. Similarly, donor organs 
clearly have higher risk characteristics including DCD donation, high terminal creatinine, donor diabetes, 
and longer cold ischemic times. This study provides the first national, risk adjusted data which quantifies 
the association between hospital costs and these donor and recipient factors.  We demonstrate a 
marked increase in hospital costs for transplantation of non-standard donor organs and high risk 
recipients.  Furthermore, there was a very poor correlation between Medicare payments and high cost 
characteristics as DRG payments are not adjusted for patient or donor risk, unless centers reach outlier 
status. Consequently, transplant margins will be reduced for centers that transplant these higher risk 
patients.   
 Previous clinical economic analyses of renal transplantation have demonstrated a substantial 
lifetime benefit of renal transplantation, compared with life time dialysis, even using non-standard 
donor organs.  Using Medicare data, Whiting and colleagues demonstrated a cost savings for the 
Medicare program, although this was mediated in part for donor and recipient characteristics.(21) The 
economic breakeven point range from 4.4 years for non-expanded criteria donor (ECD)/low- risk donors 
to 13 years for ECD.   Subsequent analyses by Matas and Schnitzler in 2004, have valued the direct cost 
savings associated with living donor transplant at $94,579, which coupled with a net gain of 3.5 quality 
adjusted life years (QALYs), suggests an overall benefit of $263,319 per transplant.(22) More recently, a 
comprehensive economic model suggested that living kidney donation was associated with societal 
benefits of $1.4 million per transplant, if the economic benefit of improved quality of life, added years in 
the workforce, and reduced life time dialysis costs were included in the analysis.(14)  However, current 
payment models for transplant centers focus only on the cost of the transplant episode; consequently, 
the long term cost savings derived from transplantation of higher risk candidates is not shared with 
transplant programs. 
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 While the long term societal benefits of kidney transplant are clear, the implications of the 
changing nature of the donor and recipient population on transplant center finances is more 
challenging.  Engelsbe and colleagues performed a single center evaluation of transplant finances at the 
University of Michigan from 1999-2005.(15)  In a multivariate analysis, reduced hospital margins were 
associated with ECD transplant, year of transplant, and the development of delayed graft function. 
Recipient and donor characteristics including race, gender, history of diabetes, age, and BMI were also 
associated with lower costs in univariate analysis; however, given the limited sample size, these 
associations were not significant in multivariate analyses. In a second single center analysis, Saidi et al. 
reported a marked increase in the incidence of DGF in ECD recipients (35.6% vs. 15.1%) and a 
corresponding 48% increase in hospital charges due to longer lengths of stay and greater need for 
inpatient dialysis.  More recently, Stahl et al. examined UHC data from 2009-12.  In this limited data set, 
they demonstrated that ECD transplantation was associated with a higher 30 day readmission rate (OR 
1.35 p<0.001) and DGF rate (OR 1.33 p<0.001).  However, there were no significant differences in 
adjusted or unadjusted cost of transplant using either ECD or KDPI index to categorize organ quality. The 
authors conclude that “recipient characteristic may be a more influential predictor of initial costs after 
transplant”. Neither Saidi nor Stahl considered the interaction of payment and hospital costs, nor did 
they examine individual components of these indexes on risk adjusted costs.  Using the UHC data, we 
identified higher costs among recipients of deceased donor kidneys from donors who were older, 
diabetic, had an elevated creatinine, or died from anoxic injuries.  All of which are more common in 
contemporary practice. Pulsatile perfusion may be one method to address the higher cost of using non-
standard organs through reduction in rates of DGF and the need for inpatient dialysis.(11) The observed 
incremental costs associated with lower organ quality are likely conservative estimates of the overall 
impact of these grafts on transplant finances as used of these grafts is frequently accompanied by higher 
rates of readmission, for-cause renal biopsy, and post-transplant renal replacement therapy.   
 In this study, we specifically examined the economic implications of recipient characteristics on 
transplant center finances. Using the EPTS score as a marker for recipient comorbidity, we demonstrate 
a strong, linear association between recipient risk and cost in deceased donor transplant.  After 
adjusting for other donor and recipient factors, high EPTS greater than 85 was independently associated 
with $5,257 in incremental costs for the transplant program.  Although, Medicare payments were higher 
for elevated EPTS patients ($2,474), this is not sufficient to compensate for the higher costs. 
Consequently, deceased donor transplantation in Medicare recipients with moderately high EPTS 
patients (51-85) and high EPTS (81-100) is likely to result in a significant expected reduction in hospital 
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margin. This loss is likely to be exacerbated as organs with higher risk characteristics (donor age, 
terminal creatinine) are appropriately transplanted into willing recipients. In living donor recipients, 
EPTS did not correlate with cost or payment data. Multiple studies have confirmed the benefits of renal 
transplant in selected elderly patients as well as the substantial barriers to accessing transplant services 
faced by these same patients.(3, 23, 24) Elderly patients, diabetics, and re-transplant patients are 
excluded from transplant waitlists or subsequently removed as too sick to transplant at much higher 
rates than other candidates.(25-28) These economic data demonstrate that hospital finances are a 
potential barrier to transplantation of at risk patients and may contribute the observed differences in 
access for these populations. The lack of appropriate adjustment of payments for highly prevalent and 
potentially expensive conditions (e.g. advanced coronary artery disease, prolonged cold ischemic time, 
and low socioeconomic status) is likely to exacerbate financial losses associated with transplantation of 
these candidates.  
Allosensitization has also been shown to decrease access to transplantation among waitlisted 
candidates despite a rising prevalence of high PRA/cPRA candidates on the waiting list. Transplantation 
in these patients requires more aggressive induction regimens and the potential need for costly plasma 
exchange. Despite the early increase in costs, however, desensitization treatments have been shown to 
be clinically effective and perhaps even cost effective. (7, 29) However, centers performing these 
procedures may face a significant economic disincentive as the degree of allosensitization was highly 
correlated with center cost. Compared with patients without alloantibodies, increasing PRA in deceased 
donor transplant incremental costs between $3,638-$9097 per transplant.  Similar findings were 
demonstrated in the living donor population, in which high PRA candidates were associated with 
reductions in incremental costs ranging from $4,708-$17,781.  Despite the marked increased cost of 
these transplants, there was no difference in payments for either deceased or living donor transplants 
performed on Medicare patients.  It was not possible to determine if these patients underwent specific 
desensitization protocols, although the benefits of 0-ABDR mismatch organs were capture for patients 
that were allocated these organs.  
 The variation in risk adjusted costs following surgical procedures has been widely reported 
nationally using health care payment data.  Englesbe and colleagues evaluated variation in costs among 
43,393 kidney transplant patients, of which 35% were classified by the authors as “high cost” patients 
based on Medicare payment including outlier payments and readmission.(30)  The incidence of high cost 
patients varied from 5% to 50% between medical centers. The proportion of high cost patients was 
found to be inversely proportional to risk adjusted outcomes, such that the centers with the best risk 
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adjusted outcomes reported the lowest costs. Among the factors that contribute to higher costs is the 
incidence of post-transplant complications. The cost of early post-operative complications in kidney 
transplantation, for example, is significant with sepsis increasing costs by up to $134,000.(31, 32) More 
recently, Irwin examined the variation in payments to centers with a large private transplant network. 
Average payment for the transplant episode varied from 54% to 154% of the median payment 
($233,532).  These differences were driven, in part, by case mix, access to living donors, length of stay, 
and access to preemptive transplant.  This investigation demonstrates a marked variation in the facility 
reported cost of transplant care among transplant programs even after adjusting for donor and recipient 
factors. The ratio of observed to expected costs ranged from 0.47 to 1.64 at the center level. The 
etiology of the marked variation in the risk-adjusted costs differences remains to be completely 
explained, but likely reflects medical and surgical care patterns including choice of induction agents, 
underlying socioeconomic differences, and the incidence and management of complications.  The study 
also demonstrates the poor correlation between average center-level cost and actual Medicare 
payments, reflecting the limited adjustment of payments for differences in patient characteristics, donor 
quality, and necessary (or potentially unnecessary) clinical care.   
This study has several limitations common to all studies which examine large data sets. The UHC 
data were derived from hospital charge masters and adjusted to costs using intermediate product cost-
to-charge ratios.  This may differ from activity based costing estimates within specific institutions.  
Second, the tracking and attribution of the organ acquisition cost differed between institutions.  These 
differences are unlikely to impact the estimates of cost or payment data.  However, direct estimate of 
transplant center margins may be inaccurate as this requires that organ acquisition cost payments are 
added to the hospital payment.  Unfortunately, these costs are not reported in standard Medicare 
analytic files and therefore, we did not analyze individual transplant center margins for this analysis. 
Third, this analysis focused solely on the technical component of the cost of transplant. There are 
additional costs associated with high cost recipients (increased professional changes, pharmacy charges 
for immunosuppression, dialysis for delayed graft function) that may be considered within global 
contracts but are delivered outside of the inpatient setting. Consequently, the economic implications of 
recipient severity of illness and donor quality may be greater than that captured in this analysis. Fourth, 
Medicare data are available for a limited portion of the population (20% of all living donor recipients). 
This may bias the results slightly as private payers provide better reimbursement.  However, the trends 
identified in this analysis are likely robust as the majority of payers employ minimally adjusted case 
rates.   Finally, with respect to the structure of our economic models, alternatives to ordinary least-
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squares (OLS) models, such as regressions estimating the determinants of the natural log of Medicare 
payments, may be more efficient but also may produce biased estimates and are difficult to interpret.  
Because we have access to cost data for very large samples, we employ the unbiased estimator.  Our 
past work has demonstrated nearly identical results with OLS cost regression and regressions on the 
natural log of Medicare payments,(33) and OLS has become our standard in analyses of the economic 
impact of complications in transplantation.(34, 35) 
 In conclusion, changes in donor and recipient characteristics have increased costs and eroded 
profitability for renal transplant nationally.  Despite the clear long term benefit of transplantation, even 
among higher risk patients, transplant centers face significant economic disincentives. Policy makers 
should consider the creation of risk adjusted payment for renal transplant, similar to that of liver and 
heart transplant, to ensure that access is reserved for expensive but deserving candidates. The inclusion 
of supplemental payments for providers that successfully utilize marginal donor organs (e.g. KPDI>85) 
would ensure that financial considerations no longer contribute to organ discard but, instead, drive 
innovation.   
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Figure Legends 
 
Figure 1: Univariate analysis of the variation in the median total cost of living donor and deceased donor 
transplant procedures performed in University HealthSystem Consortium centers across Expected Post Transplant 
Survival (EPTS) quartiles. 
 
Figure 2A and 2 B: Association between observed cost of renal transplant center and risk adjusted expected costs 
for deceased donor kidney transplant (Figure 2A) and living donor (Figure 2B) compared with average center 
annual volume of kidney transplant. 
 
Figure 3: Comparison of median center total cost of the transplant episode including organ acquisition cost and 
Medicare payment exclusive of organ acquisition cost for deceased (Figure 3A) and living (Figure 3B) donor 
transplant. 
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Table 1. Demographic and clinical characteristics of transplant recipients, by donor type, among patients transplant in centers within the 
University HealthSystem Consortium are presented for the overall population and for patients transplant between 2002-3 and 2012-13.   
  Deceased Donor Recipients Live Donor Recipients 
  UHC Total 2002-2003 2012-2013 UHC 2002-2003 2012-2013 
N=53,862 N=10,558 N=27,738 N=36,715 N=8,415 N=18,408 
  
% 
(Mean+SD) 
% 
(Mean+SD) 
%  
(Mean+SD) 
% 
(Mean+SD) 
% 
(Mean+SD) 
%  
(Mean+SD) 
Recipient Characteristics             
EPTS Score Rank     ǂ     ǂ 
  0-20 24.3 29.8 23.6 44.6 31.6 30 
  21-50 33.2 34.6 33.0 33.6 23.2 21.9 
  51-85 31.1 28.5 31.5 19.1 21.2 20.8 
  85-100 11.4 7.2 12.0 2.7 16 17.1 
Female Gender 39.4 39.5 39.1 39.8 42 39.5Ɨ 
Race     ǂ     ǂ 
   Caucasian 47.3 51.7 47 69.5 71.6 69.2 
   African-American 32.9 30.2 33.1 14.1 13.8 14.3 
   Other 19.8 18.2 19.9 16.3 14.6 16.5 
BMI (kg/m2)     ǂ     ǂ 
   <18.5 2.1 2.6 2.1 2.8 3.1 2.8 
   18.5-24.9 30.7 34.9 30.2 34.2 37.1 33.8 
   25-29.9 33.6 33 34 31.9 30.5 32.3 
   30-35 22.1 18.8 22.4 19.8 17.4 20.2 
   >35 10.7 8.3 10.7 9.5 7.7 9.7 
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   Unknown 0.8 2.4 0.6 1.7 4.2 1.2 
Payer Type   ǂ    
  Medicare 65.2 61.6 66.5 35.5 35.8 35.3 
  Private 29.4 32.7 28.2 59.8 59.2 60.1 
  Other 5.4 5.7 5.3 4.7 5.0 4.6 
 
Table 1. Demographic and clinical characteristics of transplant recipients, by donor type, among patients transplant in centers within the 
University HealthSystem Consortium are presented for the overall population and for patients transplant between 2002-3 and 2012-13.   
Cause of ESRD     ǂ     ǂ 
  Diabetes 25.3 23 25.5 21 21.4 20.9 
  Glomerulonephritis 19.1 19.8 18.7 25.1 24.9 25 
  Hypertension 25.2 23.2 25.7 16.7 14.9 17.3 
  Polycystic kidney disease 8.1 7.8 8.2 10.9 9.7 11.1 
  Other 22.4 26.2 22 26.3 29.2 25.8 
Peripheral vascular diseases 4 3.5 4.4ǂ 3.3 3.5 3.2 
Previous transplant 12.2 11.9 12.3 10.4 10.1 10.4 
Work Status     ǂ     ǂ 
  Working 20.6 6.2 24 35.9 11.4 42.9 
  Not Working 60 16.6 69.6 45.1 15.8 53.5 
  Unknown 19.5 77.2 6.4 19 72.7 3.6 
Panel Reactive Antibody (PRA,cPRA)     ǂ     ǂ 
   0-20 77.7 85.6 77.9 90 95.1 89.8 
  21-50 7.1 5.3 7.2 4.4 2.2 4.6 
  51-80 5.7 4.2 5.7 3.2 1.6 3.2 
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  81-90 4.4 2.4 4.2 1 0.5 0.9 
  91-97 3.3 1.7 3.2 0.8 0.4 0.9 
  98-100 1.8 0.9 1.8 0.7 0.3 0.7 
Donor and Transplant Characteristics             
Age (Mean) 38.6 (16.8) 38.1 (16.9) 38.7 (16.7)* 41.5 (11.5) 40.4 (10.9) 41.6 (11.5)ǂ 
Female Gender 40.2 41.8 39.6ǂ 60 58.3 59.9* 
Race     ǂ     * 
   Caucasian 70.8 73.4 70.4 72.3 73.4 72.1 
   African-American 13.9 12.2 14.3 12.3 12.7 12.4 
   Other 15.4 14.4 15.3 15.4 14 15.5 
Diabetes mellitus 52.7 14.7 60.3ǂ 0.1 0.02 0.05 
Diabetes mellitus missing information 47.3 85.3 39.7ǂ 99.9 99.98 99.95 
Table 1. Demographic and clinical characteristics of transplant recipients, by donor type, among patients transplant in centers within the 
University HealthSystem Consortium are presented for the overall population and for patients transplant between 2002-3 and 2012-13.   
Hypertension 40.3 34.1 41.6ǂ 2.1 0.3 2.4ǂ 
Donation after cardiac death 12.1 5.2 13.3ǂ -- -- -- 
Donor Cause of Death     ǂ       
  Cerebrovascular/Stroke  39.5 45.5 38.1 -- -- -- 
  Anoxia 22.1 12.4 23.4 -- -- -- 
  Head Trauma 36.1 40.3 36 -- -- -- 
  CNS Tumor 0.3 0.4 0.3 -- -- -- 
  Other/Unknown 2 1.6 2.1 -- -- -- 
HLA mismatches     ǂ     ǂ 
  Zero A, B, and DR 12.3 16.6 13.1 8.8 9.9 8.4 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
  Zero DR 15.7 16.6 15.3 17.7 17.6 17.8 
Cytomegalovirus sero-pairing     ǂ     ǂ 
  Donor - / Recipient - 12.1 11.6 12.3 22.3 20.8 22.5 
  Donor - / Recipient + 24 23.4 24.1 19.6 18.5 19.4 
  Donor + / Recipient - 17.8 16.6 18.1 15 13.9 15 
  Donor + / Recipient + 41.9 39.9 41.4 32.6 32.1 32 
Donor Terminal Creatinine     *    
  Creatinine (Mean) 1.1 (0.9) 1.07 (1.01) 1.14 (0.88)ǂ -- -- -- 
  Missing 0.1 0.2 0.04ǂ -- -- -- 
Pumped  40.8 26.0 43.4ǂ -- -- -- 
Living Donor / Recipient Relationship        ǂ 
   Unrelated -- -- -- 29.8 22.0 30.8 
   Biologically Related -- -- -- 56.7 64.8 55.7 
   Other Related -- -- -- 13.5 13.3 13.5 
Paired -- -- -- 4.2 0.5 4.6ǂ 
 
P-values:  * P 0.002-0.04;  Ɨ P 0.0001-0.001; ǂP < 0.0001  comparing 2002-3 with 2012-3 
 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 2.  Multivariate analysis of the costs of transplantation among transplants performed at University 
HealthSystem Consortium centers (2002-2013) 
  Deceased Donor Living Donor 
Parameter Estimate P-Value Estimate P-Value 
Recipient Characteristics   
  EPTS Score Rank 
0-20 Reference       
21-50 $1,096 0.005 -$461 0.25 
51-85 $2,292 <.0001 $278 0.61 
85-100 $5,257 <.0001 $1,312 0.23 
Female  -$1,589 <.0001 -$469 0.18 
Race         
  Caucasian Reference       
  Black -$434 0.23 $2,011 0.03 
  Other $6,588 <.0001 -$997 0.17 
BMI          
  <18.5 $1,819 0.075 -$95 0.93 
  18.5-24.9 Reference       
  25-29.9 $1,062 0.003 $587 0.16 
  30-35 $2,292 <.0001 $1,814 0.0001 
  >35 $2,037 0.0001 $2,139 0.001 
  Unknown $4,420 0.006 $10,263 <.0001 
Cause of Disease         
  Diabetes Reference       
  Hypertension $1,280 0.004 $2,582 <.0001 
  Glomerulonephritis -$451 0.36 -$1,980 0.0006 
  Polycystic Kidney Disease -$1,776 0.005 -$2,105 0.002 
  Other -$277 0.56 -$690 0.21 
Peripheral Vascular disease -$436 0.56 $2,231 0.02 
Working at Transplant         
  No Reference       
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  Yes -$1,923 <.0001 -$2,690 <.0001 
  Unknown -$4,819 <.0001 -$7,594 <.0001 
PRA/cPRA         
  0-20 Reference       
  21-50 $3,638 <.0001 $4,700 <.0001 
  51-80 $5,558 <.0001 $8,080 <.0001 
  81-90 $5,002 <.0001 $10,355 <.0001 
  91-97 $8,785 <.0001 $13,230 <.0001 
  98_100 $9,097 <.0001 $17,784 <.0001 
Table 2, continued.  Multivariate analysis of the costs of transplantation among transplants performed 
at University HealthSystem Consortium centers (2002-2013) 
Donor Characteristics   
Age (per year) $62 <.0001 $3 0.84 
Female -$717 0.02 -$818 0.02 
Race         
  Caucasian Reference       
  Black -$1,511 0.001 $789 0.42 
  Other $2,595 <.0001 $1,426 0.05 
Diabetes $3,370 <.0001 -$9,713 0.19 
Hypertension $665 0.04 $1,610 0.17 
Donation after Cardiac Death $6,182 <.0001 -- -- 
Cause of death         
  Anoxic Injury Reference       
  Cerebrovascular Accident -$3,040 <.0001 -- -- 
  Head Trauma -$2,322 <.0001 -- -- 
  CNS Tumor -$980 0.71 -- -- 
  Other -$1,618 0.12 -- -- 
HLA 0 Mismatch -$4,332 <.0001 -$3,799 <.0001 
HLA 0-DR Mismatch -$2,968 <.0001 $426 0.34 
CMV Donor-Recipient Mismatch         
  Recipient Neg / Donor Neg Reference       
  Recipient Pos / Donor Neg $1,110 0.03 $1,274 0.01 
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  Recipient Neg / Donor Pos $784 0.15 -$894 0.11 
  Recipient Neg / Donor Pos $67 0.90 -$947 0.05 
  Missing -$935 0.25 -$826 0.19 
Terminal Creatinine (mg/dl) $956 <.0001 -- -- 
Donor Creatinine Missing $14,115 0.0118 -- -- 
Pumped -$2,039 <.0001     
Donor-Recipient Relationship        
  Unrelated     Reference   
  Related Biologically -- -- -$852 0.04 
  Related-Other -- -- -$389 0.49 
Paired -- -- $3,330 0.0002 
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Table 3. Variation in the ratio of Observed:Expected (O:E) cost of deceased and living donor kidney transplant by UNOS region. Cost was 
adjusted for donor, recipient, and transplant factors using multivariate modeling. 
 
 Deceased Donor Living Donor 
Regions Predicted Cost O:E Cost Predict Cost O:E Cost 
Region 1 $106,486 0.83 $93,553 0.90 
Region 2 $105,474 1.05 $94,048 1.17 
Region 3 $103,108 0.93 $93,785 0.93 
Region 4 $106,384 0.96 $94,598 0.93 
Region 5 $108,441 1.08 $92,964 0.98 
Region 6 $105,743 1.02 $91,422 1.02 
Region 7 $105,480 1.07 $93,666 1.01 
Region 8 $105,846 1.01 $93,132 1.10 
Region 9 $105,585 0.93 $93,677 0.85 
Region 10 $104,288 1.13 $95,109 1.14 
Region 11 $104,144 0.85 $93,704 0.86 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 4. Association of donor and recipient characteristics with Medicare payments for kidney 
transplantation (2002-2013) 
  Deceased Donor Living Donor 
 Parameter Estimate P-Value Estimate P-Value 
Recipient Characteristics   
EPTS Score Rank         
0-20 Reference       
21-50 $925 0.0008 $588 0.29 
51-85 $1,626 <.0001 $1,198 0.06 
85-100 $2,475 <.0001 $1,104 0.29 
Female  -$123 0.55 $1,133 0.01 
Race         
  Caucasian Reference       
  Black $1,218 <.0001 $1,685 0.09 
  Other $1,454 <.0001 -$823 0.34 
BMI        
  <18.5 $1,571 0.02 $932 0.46 
  18.5-24.9 Reference       
  25-29.9 -$369 0.13 $595 0.26 
  30-35 -$189 0.49 -$278 0.65 
  >35 $526 0.13 $808 0.33 
  Unknown $4,969 <.0001 $17,872 <.0001 
Cause of Disease         
  Diabetes Reference       
  Hypertension $71 0.81 $190 0.78 
  Glomerulonephritis $1,646 <.0001 $587 0.42 
  Polycystic Kidney Disease -$135 0.76 -$1,258 0.22 
  Other $2,137 <.0001 $3,000 <.0001 
Peripheral Vascular disease $542 0.26 -$1,096 0.28 
Working at Transplant         
  No Reference       
  Yes $89 0.74 $1,221 0.03 
  Unknown $7,128 <.0001 $6,360 <.0001 
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PRA/cPRA         
  0-20 Reference       
  21-50 -$231 0.54 $123 0.90 
  51-80 $0 0.99 $1,983 0.07 
  81-90 -$631 0.19 $899 0.65 
  91-97 -$110 0.83 $1,829 0.37 
  98_100 -$70 0.92 $4,709 0.01 
Donor Characteristics   
Age (per year) $26 0.0002 $31 0.11 
Female -$343 0.10 -$860 0.05 
Table 4, continued. Association of donor and recipient characteristics with Medicare payments for 
kidney transplantation (2002-2013) 
Race         
  Caucasian Reference       
  Black $724 0.01 $912 0.39 
  Other $1,201 <.0001 $2,263 0.01 
Diabetes -$1,046 <.0001 -$1,331 0.88 
Hypertension -$209 0.32 $307 0.84 
Donation after Cardiac Death $299 0.34 -- -- 
Cause of death         
  Anoxic Injury Reference       
  Cerebrovascular Accident $673 0.01 -- -- 
  Head Trauma -$149 0.58 -- -- 
  CNS Tumor $6,585 0.0003 -- -- 
  Other $637 0.36 -- -- 
HLA 0 Mismatch -$269 0.43 -$1,165 0.17 
HLA 0-DR Mismatch -$943 0.0006 $588 0.30 
CMV Donor-Recipient Mismatch         
  Recipient Neg / Donor Neg Reference       
  Recipient Pos / Donor Neg $571 0.11 $328 0.64 
  Recipient Neg / Donor Pos $5 0.99 $744 0.34 
  Recipient Neg / Donor Pos $796 0.01 $1,104 0.09 
  Missing $1,855 0.001 $666 0.44 
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Terminal Creatinine (mg/dl) $279 0.01 -- -- 
Donor Creatinine Missing $3,174 0.42 -- -- 
Pumped -$1,768 <.0001     
Donor-Recipient Relationship        
  Unrelated     Reference   
  Related Biologically -- -- $296 0.58 
  Related-Other -- -- $2,397 0.003 
Paired -- -- $5,956 <.0001 
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Figure 1 
 
Univariate analysis of variation in the median total cost of living donor and deceased donor transplant 
procedures performed in University HealthSystem Consortium centers across Expected Post Transplant Survival 
(EPTS) quartiles.  
 
 
 
 
 
 
 
 
$80,000 
$85,000 
$90,000 
$95,000 
$100,000 
$105,000 
$110,000 
$115,000 
<20% 20-50% 51-85% >85% 
M
e
a
n
 C
o
st
 o
f 
T
ra
n
sp
la
n
t 
EPTS Category 
Living Donor 
Deceased Donor 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
 
 
Figure 2.  Association between the ratio of observed to risk-adjusted expected costs of deceased donor (A) and 
living donor (B) kidney transplantation, according to annual center transplant volume  
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Figure 2B                                 
Figure 3. 
Comparison of median center total cost of the transplant episode including organ acquisition cost and Medicare 
payment exclusive of organ acquisition cost for deceased (A) and living (B) donor transplant.  
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Figure 3B 
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